We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume |
---|---|---|---|---|---|
VRAX | Virax Biolabs Group Ltd | 2.70 | 1.63 | 152.34% | 10,750,333 |
AEMD | Aethlon Medical Inc | 0.9445 | 0.5059 | 115.34% | 15,636,074 |
MRKR | Marker Therapeutics Inc | 5.33 | 1.68 | 46.03% | 1 |
AYRO | AYRO Inc | 1.18 | 0.2801 | 31.13% | 897,118 |
KITT | Nauticus Robotics Inc | 0.18 | 0.042 | 30.43% | 21,087,329 |
ISPC | iSpecimen Inc | 0.415 | 0.0944 | 29.44% | 4,649,771 |
VNDA | Vanda Pharmaceuticals Inc | 6.02 | 0.97 | 19.21% | 296,697 |
SXTP | 60 Degrees Pharmaceuticals Inc | 0.3365 | 0.0506 | 17.70% | 113,220 |
CJJD | China Jo Jo Drugstores Inc | 3.00 | 0.45 | 17.65% | 1 |
MSGM | Motorsport Games Inc | 2.70 | 0.37 | 15.88% | 1,286,578 |
WKEY | WISeKey International Holdings AG | 2.45 | 0.32 | 15.02% | 67 |
Phase 1 Clinical Trials of the Hemopurifier® Designed to Include Patients With Solid Tumors Who Have Stable or Progressive Disease During Anti-PD-1 Monotherapy Treatment, Such as Keytruda® of Opdivo® Interested Clinical Sites Have Initiated Submissions For Ethics Committee Review SAN DIEGO, June 3, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today provided the following update on its planned phase 1 safety, feasibility and dose-finding clinical trials of its Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, ...
The offering is comprised of 61,538,461 shares of the Company’s common stock (or pre-funded warrants in lieu of shares of common stock). Each share of common stock or pre-funded warrant will be sold with one Series A Warrant to purchase one share of common stock at an exercise price of $0.22 per share (the “Series A Warrants”) and one Series B Warrant to purchase one share of common stock at an exercise price of $0.22 per share or, pursuant to an alternative cashless exercise option, three shares of common stock at a price of $0.001 per share (the “Series B ...
BEIJING, June 4, 2024 /PRNewswire/ -- MicroAlgo Inc. (NASDAQ: MLGO) (the "Company" or "MicroAlgo"), today announced that MicroAlgo and WiMi will jointly establish a micro-consciousness quantum research center. It will integrate physics, mathematics, medicine, genetics, computer science, biology, polymer chemistry, philosophy, psychology, sociology, and many other disciplines to form a comprehensive research institute based on various disciplines centered on consciousness.
VANCOUVER, BC, June 5, 2024 /PRNewswire/ -- Siyata Mobile Inc. (Nasdaq: SYTA, SYTAW) ("Siyata" or the "Company"), a global developer and vendor of Push-to-Talk (PTT) over Cellular (PoC) handsets and accessories, today announced its partnership with JD Telecom, a premier telecom solutions provider of commercial-grade vehicle solutions and a strategic distribution partner for T-Mobile, to expand distribution of its SD7 handsets, VK7 Vehicle Kits and related components.
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 70,941.83 | -135.46 | -0.19% | 1.39T | 3,561,374,178 |
ETH | Ethereum | 3,847.99 | -16.22 | -0.42% | 462.38B | 1,921,750,831 |
BNB | Binance Coin | 707.33 | 8.68 | 1.24% | 111.73B | 447,274,721 |
USDT | Tether USD | 0.99988 | -0.00011 | -0.01% | 97.83B | 229,325,304 |
SOL | Solana | 172.40 | -1.04 | -0.60% | 76.02B | 651,332,990 |
STETH | stETH | 3,847.60 | -15.07 | -0.39% | 37.72B | 5,232,370 |
XRP | Ripple | 0.5239 | -0.0017 | -0.32% | 28.59B | 226,017,174 |
USDC | USD Coin | 0.99999 | -0.00001 | 0.00% | 28.07B | 859,809,183 |
TONCOIN | Wrapped TON Coin | 7.30 | 0.124409 | 1.73% | 25.29B | 125,710,872 |
DOGE | Dogecoin | 0.162 | -0.00108 | -0.66% | 23.21B | 167,644,749 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions